Table 2 Main outcome data of studies included in the meta-analysis.

From: Efficacy and safety of rectal nonsteroidal anti-inflammatory drugs for prophylaxis against post-ERCP pancreatitis: a systematic review and meta-analysis

Study

Severity

Amylase (mean ± SD)

Hyperamylasemia

Pain

Complications

Deaths

Any

Mild

Moderate to severe

2 h after ERCP

24 h after ERCP

Bleeding

Perforation

Cholangitis

Murray et al.

I: 7 C: 17

I: 7 C: 15

I: 0 C: 2

I: 313 ± 398.55 C: 400 ± 702.7

I: 321 ± 597.85 C: 507 ± 943.92

NA

None

None

None

None

None

Sotoudehmanesh et al.

I: 7 C: 15

I: 7 C: 10

I: 0 C: 5

I: 472.70 ± 92.6 C: 494.30 ± 105.2

NA

NA

None

None

None

None

None

Montano Loza et al.

I: 4 C: 12

None

None

I: 148.22 ± 190.60 C: 240.73 ± 256.20

NA

I: 13 C: 28

None

None

None

None

None

Khoshbaten et al.

I: 2 C: 13

NA

NA

I: 310.28 ± 320.62 C: 667.80 ± 1034.16

I: 324.22 ± 331.65 C: 948.86 ± 1269.69

NA

None

None

None

None

None

Elmunzer et al.

I: 27 C: 52

I: 14 C: 25

I: 13 C: 27

NA

NA

NA

None

I: 4 C: 7

None

None

None

Dobronte et al.

I: 11 C: 11

I: 9 C: 10

I: 2 C: 1

NA

NA

NA

None

None

None

None

None

Otsuka et al.

I: 2 C: 10

I: 2 C: 7

I: 0 C: 3

NA

NA

I: 16 C: 19

I: 4 C: 20

None

None

None

None

Alabd et al.

I: 4 C: 7

I: 3 C: 6

I: 1 C: 1

NA

NA

NA

None

None

None

None

None

Dobronte et al.

I: 20 C: 22

I: 16 C: 18

I: 4 C: 4

NA

NA

I: 81 C: 79

None

None

None

None

I: 0 C: 1

Patai et al.

I: 18 C: 37

I: 15 C: 33

I: 3 C: 4

NA

NA

I: 61 C: 66

None

I: 9 C: 3

I: 1 C: 0

I: 2 C: 2

I: 3 C: 4

Andrade-Davila et al.

I: 4 C: 17

I: 3 C: 14

I: 1 C: 3

I: 141.9 ± 92.6 C: 216.5 ± 105.2

NA

I: 19 C: 81

None

I: 2 C: 3

None

None

None

Lua et al.

I: 7 C: 4

I: 4 C: 4

I: 3 C: 0

NA

NA

NA

None

I: 1 C: 3

I: 1 C: 0

I: 2 C: 4

None

Levenick et al.

I: 16 C: 11

I: 16 C: 9

I: 0 C: 2

NA

NA

NA

None

I: 4 C: 6

I: 1 C: 0

None

I: 0 C: 3

Luo et al.

I: 29 C: 65

I: 22 C: 7

I: 48 C: 17

NA

NA

NA

None

NA

NA

NA

NA

Ucar et al.

I: 1 C: 7

I: 0 C: 3

I: 1 C: 4

NA

I: 211 ± 77 C: 463 ± 100

I: 6 C: 14

I: 5 C: 10

I: 2 C: 2

None

None

None

Hosseini et al.

I: 11 C: 17

None

None

NA

NA

NA

None

None

None

None

None

  1. I, intervention; C, control; SD, standard deviation; NA, not available; ERCP, endoscopic retrograde cholangiopancreatography; ARF, acute renal failure.